GEN Exclusives

More »

GEN News Highlights

More »
May 10, 2011

Amylin Allies with JDRF to Evaluate Co-Formulation of Symlin with Insulin

  • Amylin Pharmaceuticals and the Juvenile Diabetes Research Foundation (JDRF) inked a research collaboration to fund a series of clinical studies evaluating the potential to co-formulate Amylin’s injectable pramlintide drug Symlin® with insulin for the treatment of type 1 diabetes.

    Symlin is an analogue of the human hormone amylin and is approved for use as an adjunct to mealtime insulin therapy in patients who can’t achieve desired glucose control using optimum insulin. However, at present the two drugs need to be administered as separate injections and can’t be mixed.

    The collaboration between JDRF and Amylin will involve up to three clinical proof-of-concept trials to evaluate whether a fixed ratio of pramlintide and insulin can effectively control glucose levels and identify the optimal dose ratios. JDRF and Amylin point out that in addition to simplifying treatment, a single injection combining pramlintide and insulin may better mimic the natural physiology of the pancreas.

    The two organizations have a separate, ongoing collaboration to carry out a proof-of-concept study evaluating the human leptin analog metreleptin in patients with type 1 diabetes.

     


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Tackling Climate Change

Do you think most companies will respond positively to the People’s Climate March?